Multiple myeloma

Multiple myeloma (MM) is a malignant tumor of plasma cell characterized by overproduction of abnormal plasma cells in the bone marrow and skeletal destruction. The clinical features are bone pain, renal impairment, immunodeficiency, anemia and presence of abnormal immunoglobulins (Ig).

Myelodysplasia

Clonal hematopoietic stem cell disorders characterized by dysplasia (ineffective production) in one or more hematopoietic cell lineages, leading to anemia and cytopenia.

Total: 6

(per page)

PMID (PMCID)
26309708	OTHER
	Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy.
	Gu ZH, Xie X, Mao JJ, Guo HF. Int J Clin Exp Med. 2015;8(6):10105-8.
	Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy.
22937309 (3420444)	OTHER
	Lenalidomide-Associated ITP.
	Herold CI, Gasparetto C, Arepally GM. Case Rep Hematol. 2011;2011:638020.
	Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia.
12152995	MIXED_SAMPLE	Adult
	Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
	Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Leuk Lymphoma. 2002;43(6):1267-71.
	Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
8597611	MALE
	Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia.
	Weh HJ, Seeger D, Junge I, Hossfeld DK. Ann Hematol. 1996;72(2):81-2.
	Trisomy 8 preceding diagnosis of acute nonlymphocytic leukemia by 2 years in a patient with multiple myeloma without cytological evidence of myelodysplasia.
8213770	MALE
	Coincidental polycythemia vera and multiple myeloma: case report and review.
	Fink L, Bauer F, Perry JJ. Am J Hematol. 1993;44(3):196-200.
	The issues of clinical importance in this unusual case include the mechanisms of anemia in multiple myeloma, the difficulty in using anemia as a parameter on which to base the initiation of therapy for myeloma, and the risks of treatment-induced leukemia and myelodysplasia.
6866310	FEMALE	Middle Aged
	[Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
	Scolozzi R, Boccafogli A. Minerva Med. 1983;74(28-29):1783-5.
	A case of myelodysplasia (refractory anaemia with excessive blasts) arising 7 years after a 3 year period of intermittent monthly treatment cycles with melphalan for multiple myelomas is reported.